Ban Labs (P) Ltd.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Ban Labs (P) Ltd. - overview
Established
1966
Location
Rajkot, Gujarat, India
Primary Industry
Consumer Products
About
Ban Labs (P) Ltd. is a multifaceted company specializing in pharmaceuticals, Ayurvedic medicines, and industrial solutions, committed to innovation and quality in diverse markets. Founded in 1966, Ban Labs (P) Ltd. operates primarily in Rajkot, India.
The company focuses on developing innovative pharmaceutical products and Ayurvedic formulations. In October 2018, True North acquired a 75% majority stake in Ban Labs for approximately INR 7 billion (USD 96 million), marking a significant change in ownership and investment strategy. The company has completed a total of 1 deal, with the most recent one occurring on October 1, 2018. Ban Group of Companies provides a wide array of products and services across multiple sectors such as pharmaceuticals, Ayurvedic medicines, industrial equipment, and clean energy solutions.
Their key offerings include Active Pharmaceutical Ingredients (API) and Ayurvedic formulations, developed through a research and development center accredited by the Ministry of Science, Government of India. The pharmaceutical segment serves healthcare providers globally with innovative API solutions. Additionally, the company produces advanced technology products like the Micro Nano Bubble Generator Regenerative Turbine (DAF) Pump to enhance industrial efficiency. Personal care products including shampoos, perfumes, and facial kits are also offered, alongside sustainable clean energy products and nutraceuticals, reaching markets in North America, Europe, and Asia.
In the most recent year of 2023, Ban Labs generated a revenue of USD 7,998,810. 40, while the EBITDA for the same year was -USD 9,431,364. 30. The revenue model is supported by direct sales, B2B partnerships, and retail transactions across various sectors, enabling the company to establish a steady income stream.
Ban Labs (P) Ltd. plans to leverage the capital from the recent buyout by True North to enhance its product development and market expansion efforts. Upcoming product launches include advanced pharmaceuticals and Ayurvedic remedies designed to meet the needs of diverse consumer bases. The company also aims to enter new international markets in North America and Europe by 2025, focusing on expanding its pharmaceutical and clean energy product lines.
The recent acquisition funding will facilitate these initiatives, ensuring the company is well-positioned for sustainable growth.
Current Investors
True North
Primary Industry
Consumer Products
Sub Industries
Beauty & Hygiene
Website
www.banlab.com
Verticals
Manufacturing
Company Stage
Mature - Buyout
Total Amount Raised
Subscriber access only
Ban Labs (P) Ltd. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Buyout | Completed | Ban Labs (P) Ltd. | - | ||||||||
| Corporate Carve Out | Completed | Sesa Care Private Limited | - |
Displaying 1 - 2 of 2
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.